scholarly article | Q13442814 |
P356 | DOI | 10.1080/10717544.2017.1337823 |
P698 | PubMed publication ID | 28617150 |
P50 | author | Mohammed A Ahmed | Q56953135 |
Mohammed Elmowafy | Q58337113 | ||
Khaled Shalaby | Q83999503 | ||
Hany M. Ibrahim | Q41890363 | ||
P2093 | author name string | Ayman Salama | |
Hossam Hefesha | |||
P2860 | cites work | Nanostructured lipid carrier (NLC) based gel of celecoxib. | Q50951651 |
Lipid nanoparticles for oral delivery of raloxifene: optimization, stability, in vivo evaluation and uptake mechanism. | Q51171804 | ||
Nanostructured lipid carriers (NLC) in cosmetic dermal products. | Q52925313 | ||
PD-PK evaluation of freeze-dried atorvastatin calcium-loaded poly-ε-caprolactone nanoparticles. | Q53767751 | ||
Design and validation of a histological scoring system for nonalcoholic fatty liver disease | Q29614930 | ||
Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability | Q33578636 | ||
Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts | Q33976182 | ||
Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract | Q34190317 | ||
Intestinal lymphatic drug transport: an update | Q34328456 | ||
Formulation of a novel oxybenzone-loaded nanostructured lipid carriers (NLCs) | Q34444568 | ||
Alpha-lipoic acid-loaded nanostructured lipid carrier: sustained release and biocompatibility to HaCaT cells in vitro | Q35021953 | ||
Effect of pluronic P85 on ATPase activity of drug efflux transporters | Q37179672 | ||
Suppressor of cytokine signaling-3 (SOCS-3) and a deficit of serine/threonine (Ser/Thr) phosphoproteins involved in leptin transduction mediate the effect of fructose on rat liver lipid metabolism | Q39928700 | ||
Biopharmaceutical challenges associated with drugs with low aqueous solubility--the potential impact of lipid-based formulations. | Q40141200 | ||
Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment | Q42788473 | ||
Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics | Q43198970 | ||
Long chain lipid based tamoxifen NLC. Part I: preformulation studies, formulation development and physicochemical characterization | Q43591380 | ||
Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin | Q44415253 | ||
Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. | Q44907355 | ||
Enhancement of Bioavailability and Pharmacodynamic Effects of Thymoquinone Via Nanostructured Lipid Carrier (NLC) Formulation | Q46337926 | ||
Enhanced bioavailability of nano-sized chitosan-atorvastatin conjugate after oral administration to rats | Q46406341 | ||
Mild hepatic fibrosis in cholesterol and sodium cholate diet-fed rats | Q46418029 | ||
Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process | Q46688330 | ||
Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice | Q46711804 | ||
Liquid chromatography/mass spectrometric studies on atorvastatin and its stress degradation products | Q46773853 | ||
Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. | Q46786043 | ||
Size-dependent absorption mechanism of polymeric nanoparticles for oral delivery of protein drugs | Q47290659 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 932-941 | |
P577 | publication date | 2017-11-01 | |
P1433 | published in | Drug Delivery | Q5308838 |
P1476 | title | Atorvastatin-loaded nanostructured lipid carriers (NLCs): strategy to overcome oral delivery drawbacks | |
P478 | volume | 24 |
Q99728602 | Atorvastatin Solid Lipid Nanoparticles as a Promising Approach for Dermal Delivery and an Anti-inflammatory Agent |
Q90528642 | Development of novel rosuvastatin nanostructured lipid carriers for oral delivery in an animal model |
Q58032213 | Pharmaceutical Dispersion Techniques for Dissolution and Bioavailability Enhancement of Poorly Water-Soluble Drugs |
Search more.